BrainsWay Welcomes Richard A. Bermudes, M.D. as Chief Medical Officer
Burlington, Mass. and Jerusalem — BrainsWay Ltd. (NASDAQ: BWAY) is excited to announce the immediate appointment of Richard A. Bermudes, M.D. as its new Chief Medical Officer (CMO). Dr. Aron Tendler, M.D., who previously held the CMO position, will remain involved with the company, collaborating on key strategic research initiatives.
Insights from Leadership
"We are thrilled to have Richard join our team to guide and develop BrainsWay’s clinical strategy and product roadmap. His extensive background in TMS and brain stimulation therapies, along with over 20 years of experience as a practicing physician, makes him exceptionally qualified for this role," stated Hadar Levy, BrainsWay’s Chief Executive Officer. "We also want to express our gratitude for Dr. Tendler’s invaluable contributions to the Company over the last decade, and we are pleased that he will continue to work with the BrainsWay team on important research projects.”
Dr. Richard A. Bermudes: A Wealth of Expertise
Dr. Bermudes brings more than 20 years of groundbreaking experience in brain stimulation and innovative mental health technologies. He is widely recognized as a leader in the field of Transcranial Magnetic Stimulation (TMS). As a co-founder of a behavioral health care network that includes 24 outpatient clinics, he has played a crucial role in integrating new therapies into treatment practices and launching telehealth initiatives. Throughout his career, Dr. Bermudes has been dedicated to improving mental health through innovative care solutions.
Academic Achievements and Research Contributions
Alongside his clinical responsibilities, Dr. Bermudes is an Associate Physician at the UC Davis Department of Psychiatry and Behavioral Sciences. He is a Diplomat of the Academy of Cognitive Therapy and serves as the lead editor of the well-regarded book, “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice.” He obtained his M.D. from the University of California, San Diego, School of Medicine.
About BrainsWay and Its Innovations
BrainsWay is recognized globally as a leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is at the forefront of neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, which aims to enhance health and transform lives. Notably, BrainsWay is the first and only TMS company to receive FDA clearance for three indications, backed by pivotal clinical studies demonstrating efficacy.
Current Indications and Future Plans
Currently, BrainsWay's treatments are FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is committed to advancing its scientific leadership and building upon its extensive clinical evidence. Additional clinical trials for Deep TMS targeting psychiatric, neurological, and addiction disorders are actively in progress. Since its founding in 2003, with locations in Burlington, MA, and Jerusalem, Israel, BrainsWay has focused on increasing global awareness and ensuring widespread access to Deep TMS therapies.
Frequently Asked Questions
What is the role of Richard A. Bermudes at BrainsWay?
Richard A. Bermudes has been appointed as the Chief Medical Officer (CMO) at BrainsWay, where he will lead the clinical strategy and product roadmap.
What are the current FDA-cleared indications for BrainsWay?
BrainsWay currently has FDA clearance for treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
How long has Dr. Richard A. Bermudes been in the field of brain stimulation?
Dr. Bermudes has over 20 years of experience in pioneering brain stimulation and mental health technologies.
What significant contributions did Dr. Aron Tendler make to BrainsWay?
Dr. Aron Tendler, the previous CMO, has contributed significantly to the Company through his role and will continue to collaborate on strategic research projects.
When was BrainsWay founded?
BrainsWay was founded in 2003 and has since become a leader in noninvasive neurostimulation therapies for mental health disorders.
